Journal article
Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
- Lallemand F Santen SAS, Evry, France.
- Schmitt M Santen SAS, Evry, France.
- Bourges JL Department of Ophthalmology, Paris Descartes School of Medicine, Assistance Publique-Hôpitaux de Paris, Cochin-Hôtel-Dieu Hospital, Université Sorbonne Paris Cité, Paris, France.
- Gurny R School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
- Benita S The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, Israel.
- Garrigue JS Santen SAS, Evry, France. Electronic address: jean-sebastien.garrigue@santen.com.
- 2017-03-19
Published in:
- European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. - 2017
Cyclosporine
Emulsion
Hydrogel
Ocular delivery
Pipeline products
Solution
Academic Medical Centers
Animals
Cyclosporine
Drug Compounding
Drug Delivery Systems
Drug Industry
Eye Diseases
Humans
Immunosuppressive Agents
Ophthalmic Solutions
English
Local ocular delivery of cyclosporine A (CsA) is the preferred method for CsA delivery as a treatment for ocular inflammatory diseases such as uveitis, corneal healing, vernal keratoconjunctivitis and dry eye disease. However, due to the large molecular weight and hydrophobic nature of CsA and the natural protective mechanisms of the eye, achieving therapeutic levels of CsA in ocular tissues can be difficult. This review gives a comprehensive overview of the current products available to clinicians as well as emerging drug delivery solutions that have been developed at both the academic and industry levels.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.ejpb.2017.03.006
- PMID 28315447
- Persistent URL
- https://sonar.ch/global/documents/100442
Statistics
Document views: 36
File downloads: